{"id":"flumist-trivalent-2015-2016","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nasal congestion"},{"rate":"20-30","effect":"Runny nose"},{"rate":"10-15","effect":"Sore throat"},{"rate":"5-10","effect":"Cough"},{"rate":"1-3","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains three live, temperature-sensitive, attenuated influenza virus strains (H1N1, H3N2, and influenza B) that replicate in the cooler upper respiratory tract but cannot replicate in the warmer lower respiratory tract. This triggers both mucosal and systemic immune responses, inducing antibody and cell-mediated immunity against the three circulating influenza strains included in the formulation for that season.","oneSentence":"FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened flu virus strains intranasally.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:40.743Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention in children and adults aged 2-49 years"}]},"trialDetails":[{"nctId":"NCT02550197","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-09","conditions":"Influenza","enrollment":300},{"nctId":"NCT03143101","phase":"PHASE4","title":"Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2017-05-08","conditions":"Influenza, Healthy","enrollment":200},{"nctId":"NCT02560909","phase":"PHASE4","title":"Adjuvanted Influenza Vaccine in Stem Cell Transplant","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2015-10","conditions":"Transplantation, Influenza Vaccines","enrollment":73},{"nctId":"NCT02473510","phase":"PHASE4","title":"Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2015-06","conditions":"Influenza, Healthy","enrollment":301}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"FluMist trivalent (2015-2016)","genericName":"FluMist trivalent (2015-2016)","companyName":"MedImmune LLC","companyId":"medimmune-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened flu virus strains intranasally. Used for Influenza prevention in children and adults aged 2-49 years.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}